Clinical Trials Browser

OTHER × Interventional × Sorafenib × Clear all

NCT01187199 2026-04-16

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT03132454 2026-04-15

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05068752 2026-03-30

Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

Phase 2 Completed

10 enrolled 15 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT02298348 2026-03-23

N2013-02

Phase 1 Active not recruiting

Neuroblastoma, Recurrence

NCT07463651 2026-03-20

TROPHY-15

Phase 3 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05468359 2026-03-16

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Phase 1/2 Recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT01946529 2026-02-23

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Phase 2 Active not recruiting

24 enrolled 11 charts

Neuroectodermal Tumors, Primitive, Peripheral, Desmoplastic Small Round Cell Tumor

NCT02559778 2026-02-20

PEDS-PLAN

Phase 2 Recruiting

Neuroblastoma

NCT05669339 2026-02-18

AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Phase 2 Active not recruiting

35 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell

NCT00989469 2026-02-05

NEXIRI

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT01715441 2026-02-05

NEXIRI2

Phase 2 Completed

Gastrointestinal

Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors

NCT03211416 2026-02-05

Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer

Phase 1/2 Completed

37 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03164057 2026-01-28

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00826540 2026-01-20

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Completed

83 enrolled 10 charts

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00494182 2025-12-17

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT01871766 2025-12-17

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Phase 2 Active not recruiting

Rhabdomyosarcoma

NCT03247088 2025-12-15

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Phase 1/2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07264010 2025-12-04

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Phase 2/3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03037437 2025-09-04

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

Phase 2 Completed

Gastrointestinal

Liver Neoplasms

NCT02029001 2025-08-07

MOST plus

Phase 2 Recruiting

Neoplasm Metastasis

NCT01141309 2025-07-22

Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

Phase 2 Active not recruiting

Thyroid Diseases, Thyroid Neoplasms

NCT01754987 2025-05-04

A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective

Phase 1/2 Completed

5 enrolled 7 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT00639262 2025-05-02

Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors

Phase 1 Completed

Brain Neoplasms

NCT01840592 2025-05-02

Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03899428 2025-03-24

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05873244 2025-03-21

CXD101 in Immunotherapy-related Liver Cancer

Phase 2 Recruiting

HCC

NCT04709380 2025-02-26

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

Phase 3 Terminated

Gastrointestinal

Radiotherapy

NCT03439891 2025-02-11

Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

Phase 2 Completed

16 enrolled 27 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase 2 Recruiting

Locally Advanced Thyroid Gland Carcinoma

NCT03009461 2024-12-04

Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT06690697 2024-11-15

Combination of Toripalimab and JS004 Therapy for ccRCC

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT01906216 2024-08-28

SELECT

Phase 3 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT06221683 2024-08-22

GMCAII

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06532084 2024-08-01

SoraGVL

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT06527495 2024-07-30

Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT02856126 2024-07-23

HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC

Phase 3 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT01817751 2024-07-17

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

Phase 2 Completed

47 enrolled 13 charts

Brain Neoplasms, Glioblastoma, Glioma, Neurologic Manifestations

NCT04518852 2024-06-25

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Phase 2 Completed

Gastrointestinal

NCT03017326 2024-05-13

PHITT

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Hepatoblastoma

NCT03565536 2024-04-19

Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer

Phase 2 Completed

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT02135874 2024-03-22

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

Phase 2 Completed

16 enrolled 9 charts

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute

NCT06030895 2024-03-12

Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.

Phase NA Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01624285 2023-12-14

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT00606866 2023-11-29

MRI

Phase 3 Completed

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT00634634 2023-11-09

Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

Phase 1/2 Completed

52 enrolled 14 charts

Breast Neoplasms

NCT00496756 2023-10-26

Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer

Phase 2 Terminated

14 enrolled 6 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01703455 2023-10-19

Activity of Sorafenib in Salivary Gland Cancer

Phase 2 Completed

Salivary Gland Neoplasms